1. Scrip
  2. >>Focus On Asia

INTERVIEW: KDDF CEO On Building R&D Success, Pipelines

 
• By Jung Won Shin

The South Korean pharma industry and government are notching up efforts to pursue open innovation for successful R&D, and the state-run Korea Drug Development Fund (KDDF) is at the center of this push. The CEO of the fund, which is supported by multiple government ministries, talks to PharmAsia News about how it is supporting domestic firms to more successfully acquire and develop novel global drugs.

SEOUL - South Korean pharma and biotech companies should bring in more innovative drug compounds from overseas to raise their chances of success in developing novel products and reducing R&D costs, says the CEO of the Korea Drug Development Fund (KDDF).

"We should engage more in open innovation by buying compounds that have initially been verified from overseas. According to statistics,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

Sakaguchi’s Nobel Brings Cheer To Japan Biopharma

 
• By Lisa Takagi

Japan's latest Nobel Prize win sparks hopes for renewed investment in biopharma R&D by the national government, including in a venture co-founded by the winner.

India’s R&D Funding Push: Catalytic To De-Risking Early Innovation?

 
• By Anju Ghangurde

India rolls out amended R&D financial assistance plan targeting certain ‘priority areas’ and calls for proposals from industry and startups. While the corpus is modest, the scheme hopes to enable the ‘Innovate in India’ ecosystem and includes a co-funding provision.

Japan’s Cell Therapy Quest Goes On Despite Takeda, Novo Withdrawals

 
• By Lisa Takagi

Japan continues to see promise in iPSC and other cell therapies, despite two major firms recently announcing their withdrawal from the area and other setbacks.

Asia Deal Watch: Kyorin Collaborates On Hinge’s Multispecific Antibody For Lupus

 
• By Joseph Haas and Lisa Takagi

Plus deals involving Elix/Tohoku U., Hanmi/Gilead/Hope Health, Heartseed/Novo Nordisk, Novatim/VRise, Qurient/Synaffix, Huons/Therapex, Mochida/Itochu/AND Pharma, Sovargen/Angelini, Starpharma/Genentech, Axcelead/xFOREST and Daiichi Sankyo/Immuto.

More from Scrip

Psoriasis Submissions Iin The Bag, J&J Advances Icotrokinra Into Phase III For Ulcerative Colitis

 
• By Kevin Grogan

The company has presented the full set of positive results from the Phase IIb ANTHEM-UC trial in the inflammatory bowel disease.

Hope Medicine Ready To Bring Potential First-in-Class Endometriosis Treatment Into Phase III

 
• By Andrew McConaghie

The non-hormonal drug could be a big step forward in treating pain associated with the condition, but the Chinese company may still need a partner for its Phase III studies and eventual commercialization.

Sakaguchi’s Nobel Brings Cheer To Japan Biopharma

 
• By Lisa Takagi

Japan's latest Nobel Prize win sparks hopes for renewed investment in biopharma R&D by the national government, including in a venture co-founded by the winner.